| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 548 | 2014 |
| Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer JM Balko, LJ Schwarz, NE Bhola, R Kurupi, P Owens, TW Miller, H Gómez, ... Cancer research 73 (20), 6346-6358, 2013 | 160 | 2013 |
| Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers JT Garrett, CR Sutton, R Kurupi, CU Bialucha, SA Ettenberg, SD Collins, ... Cancer research 73 (19), 6013-6023, 2013 | 92 | 2013 |
| MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis KV Floros, JY Cai, S Jacob, R Kurupi, CK Fairchild, M Shende, CM Coon, ... Cancer research 81 (7), 1896-1908, 2021 | 88 | 2021 |
| Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma TL Lochmann, KM Powell, J Ham, KV Floros, DAR Heisey, RIJ Kurupi, ... Science translational medicine 10 (441), eaao4680, 2018 | 85 | 2018 |
| High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition J Cai, S Jacob, R Kurupi, KM Dalton, C Coon, P Greninger, RK Egan, ... Cell reports 40 (4), 2022 | 14 | 2022 |
| Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma KM Dalton, TL Lochmann, KV Floros, ML Calbert, R Kurupi, GT Stein, ... Proceedings of the National Academy of Sciences 118 (13), e2009620118, 2021 | 14 | 2021 |
| Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma KM Dalton, K Krytska, TL Lochmann, R Sano, C Casey, A D'Aulerio, ... Molecular cancer therapeutics 20 (8), 1400-1411, 2021 | 12 | 2021 |
| Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors KV Floros, S Jacob, R Kurupi, CK Fairchild, B Hu, M Puchalapalli, ... Cell Death & Disease 12 (2), 179, 2021 | 12 | 2021 |
| Pharmaceutical interference of the EWS-FLI1–driven transcriptome by cotargeting H3K27ac and RNA polymerase activity in Ewing sarcoma DAR Heisey, S Jacob, TL Lochmann, R Kurupi, MS Ghotra, ML Calbert, ... Molecular Cancer Therapeutics 20 (10), 1868-1879, 2021 | 10 | 2021 |
| Pharmacologic inhibition of SHP2 blocks both PI3K and MEK signaling in low-epiregulin HNSCC via GAB1 R Kurupi, KV Floros, S Jacob, AT Chawla, J Cai, B Hu, M Puchalapalli, ... Cancer research communications 2 (9), 1061-1074, 2022 | 4 | 2022 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4 (2): 232–245 JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... CD-13-0286, 2014 | 4 | 2014 |
| Pharmacological targeting of SUMOylation leads to cBAF complex stabilization and disruption of the synovial sarcoma signature KV Floros, J Li, JL Roberts, R Kurupi, CK Fairchild, B Hu, Y Xing, ... Cancer Research 84 (6_Supplement), 7071-7071, 2024 | | 2024 |
| Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18:: SSX transcriptome in Synovial Sarcoma KV Floros, CK Fairchild Jr, J Li, K Zhang, JL Roberts, R Kurupi, B Hu, ... bioRxiv, 2024.04. 25.591023, 2024 | | 2024 |
| Epithelial-mesenchymal transition and resistance to EGFR inhibitors S Jacob, R Kurupi, AC Faber Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC, 105-124, 2023 | | 2023 |
| MYCN-amplified neuroblastoma is addicted to iron and vulnerable to ferroptosis KV Floros, MO Johnson-Berro, R Kurupi, CK Fairchild, K Dalton, B Hu, ... Cancer Research 82 (12_Supplement), 362-362, 2022 | | 2022 |
| SHP2 inhibition-based combination targeted therapies for molecularly defined subgroups of HNSCC patients R Kurupi | | 2022 |
| Abstract PO-024: Catastrophic ATP loss underlines a metabolic combination therapy tailored for MYCN-amplified neuroblastoma KM Powell, TL Lochmann, KV Floros, ML Calbert, R Kurupi, GT Stein, ... Cancer Research 80 (23_Supplement), PO-024-PO-024, 2020 | | 2020 |
| Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database C Vigil Gonzales, R Velarde, SP Neciosup, M León, H Gómez Moreno, ... Elsevier Inc., 2010 | | 2010 |
| Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer R Kurupi, HL Gómez Moreno, CL Arteaga | | |
